Skip to main content

Kayyem Jon Faiz's Form 4 filing

Inhibrx Biosciences, Inc. (INBX) · filed Jun 4, 2024

Accession no.
0002007919-24-000006
Filed
Jun 4, 2024
Trade date
May 31-Jun 4, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions. Open-market purchases total $4.93M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kayyem Jon FaizCIK 0001366268Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 31, 2024Common StockPPurchaseAcquired+70,193$16.14F1+$1,132,915.02876,268Indirect
Jun 3, 2024Common StockPPurchaseAcquired+46,792$16.61F2+$777,215.12923,060Indirect
Jun 3, 2024Common StockPPurchaseAcquired+80,738$17.90F3+$1,445,210.21,003,798Indirect
Jun 4, 2024Common StockPPurchaseAcquired+65,337$17.44F4+$1,139,477.281,069,135Indirect
Jun 4, 2024Common StockPPurchaseAcquired+23,726$18.24F5+$432,762.241,092,861Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

F2

The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

F3

The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

F4

The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

F5

The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)